Spinal cord stimulation (SCS) is an evidence-based, reversible but invasive procedure for the treatment of chronic pain syndromes: for example, in patients with failed-back-surgery syndrome or complex regional pain syndrome. A more recent, similar technique uses high-frequency stimulation for SCS and follows a different mechanism of action that does not result in paresthesia. This Technical Note and video present surgical instructions of a "2-way cut-down" technique for a high-frequency SCS trial period and permanent implantation of an implantable pulse generator.
U p to 30% of patients who undergo spinal surgery acquire failed-back-surgery syndrome. 1 Another large percentage of the population suffers from chronic low back pain and leg pain, which are very common conditions (3% to 10%) 2 and are increasing because of demographic changes; thus the health and economic burdens are also increasing. 3 One of several established treatments for chronic low back pain and other pain conditions, including neuropathic pain syndromes, is spinal cord stimulation (SCS). Conventional, tonic SCS with low-frequency stimulation (w40 to 60 Hz) is an evidence-based method for the treatment of failedback-surgery syndrome and other chronic pain syndromes such as complex regional pain syndrome. 4 The corresponding spinal region of the pain area is stimulated to paresthesia to mask pain perception. In contrast, with high-frequency SCS (10 kHz, known as HF10 therapy), paresthesia is neither observed nor intended, as the stimulation is beneath the neuronal threshold for sensitive perceptions 5 (Tables 1 and 2) . Furthermore, randomized controlled trials show the superiority of HF SCS over conventional tonic SCS regarding pain relief. 6 
Surgical Technique
Step 1: Temporary Stimulation for Trial Period
The patient is placed in a prone position and covered with sterile drapes. About 30 minutes before skin incision, a single shot of antibiotics (e.g., cefuroxime) is administered. Correct spinal positioning and the appropriate vertebral level (thoracic vertebra 8 [T8] to T10) for the planned placement of the leads is determined by fluoroscopy.
We aim for the midline of the epidural space at lumbar 1/2 (L1/2) or L2/3. The skin entry point should be 2 pedicles lower, slightly para-midline. The skin is incised, and 2 Tuohy needles are inserted through the ligamentum flavum into the epidural space ( Fig 1) . The percutaneous lead (Octrode; Nevro) is introduced at a shallow angle of w30 to prevent contusions to the dura or spinal cord. Once the lead is within the epidural space, it is advanced to the desired vertebral level (T8/9) in midline by fluoroscopic guidance (Figs 2 and3) . The procedure is repeated for another lead that is recommended to be placed in a more caudal and midline position (T9/10) with respect to the first lead.
A small incision to the lumbar fascia is made. The leads are then fixed to the fascia by anchors and are connected to originator/recipient cables for impedance measurements (Fig 4) . If the impedance is within the desired range, the leads are fixed completely by tightening the set screws at the anchor, turning the torque wrench until it clicks. If the impedance is insufficient, the leads have to be repositioned before fixation.
When loose ends of the lead have been wiped clean, lead extensions are connected via an extension adaptor. The loose ends of the lead extension are then inserted into the hollow part of a tunneling tool and guided 10 to 15 cm subcutaneously in a lateral direction to the planned position of the internal pulse generator (IPG) pocket, and the extension lead adaptors are placed. For preventing infections in the planned IPG pocket site, the loose ends of the extension leads are guided w15 cm cranio-laterally to a temporary exit site that passes the skin surface ( Fig 5) . For less postoperative wound pain, local anesthetics (e.g., bupivacaine) can be injected along the tunneling route. Once the tunneling tool has exited the skin, the sharp tip is taken off, and the extension leads are gently pulled through the straw, which is then removed. A strain relief loop is prepared for the leads in the wound, and a final check for lead positioning is made by fluoroscopy.
The wounds are closed and covered with sterile wound dressings, and the extension leads are connected to the external pulse generator (EPG). After using the lead location tool in the appropriate software, it is necessary to connect the proximal lead, which is blue, to lead port 1 of the EPG. Parameters for stimulation such as the pulse amplitude can then be changed and adjusted by the software (Fig 4) .
Step 2: Permanent Stimulation via IPG Implantation
During the trial period of 7 to 14 days, pain relief is monitored and evaluated. If there is significant pain reduction (>50%), the permanent implantation of an IPG is scheduled. The extracorporeal part of the extension leads is cut off under sterile conditions. A subcutaneous part of the extension leads remains until IPG implantation. Before surgery, the pocket site should be marked with the patient in a sitting position. A subcutaneous pocket (gluteal or abdominal region) is prepared, and its size is checked with a dummy the size of the IPG (Fig 6) . The extension lead adaptors are disconnected, and the IPG is connected to the epidural leads. Again, the proximal leg (blue) is connected to the lower port of the IPG. Finally, the IPG is inserted, and the wound is closed and covered with sterile wound dressings (Fig 7) . Recharging (and if necessary, reprogramming) of the IPG is done via transcutaneous transduction (Video 1, Table 3 ).
Discussion
Recent advancements in the field of neuromodulation have yielded significant improvements in treatment outcomes and have expanded the application of SCS treatment to a wider range of chronic pain patients. As different studies have found, high-frequency (HF) SCS is a superior alternative to conventional, low-frequency SCS. 6, 7 HF SCS yields several advantages such as a different mechanism of action that does not require paresthesia to mask pain. There seems to be modulation of the dorsal horn and the wide-dynamic-range neurons. 5 Furthermore, there is evidence that the pain-reducing effect of HF SCS is vast and of long endurance. 8 In addition, this technique may serve as a treatment option for pain-refractory patients who experience longduration medical management and previous spinal surgery. 9 There is some evidence that HF SCS may be more cost-effective than other treatment procedures (conventional SCS or pain medication) for the same indications when comparing cost and quality-adjusted life years. 10 Furthermore, HF SCS reduces opioid usage in most cases. 11 SCS patients report greater improvements to pain, quality of life, and activity levels and have a higher return-to-work rate than those receiving conservative treatment. 12 The HF SCS procedure described here is surgically undemanding, and the placement of the leads, which is crucial for the success of the operation, can be controlled objectively by fluoroscopy. Furthermore, it can be performed under general anesthesia. In contrast, conventional SCS requires waking the patient during the intervention to subjectively map the pain area and success of paresthesia. 
